Deutsche Bank AG Buys 216,882 Shares of Amicus Therapeutics, Inc. $FOLD

Key Points

• Deutsche Bank AG has increased its stake in Amicus Therapeutics by 26.4%, owning over 1 million shares worth approximately $8.5 million after additional purchases in Q1.
• Shares of Amicus Therapeutics have seen a 3.9% increase recently, with analysts providing mixed ratings and adjusting price targets ranging from $9.00 to $22.00.
• Institutional investors like Allspring Global Investments and Victory Capital have also significantly boosted their positions in Amicus Therapeutics during the first quarter.

Deutsche Bank AG grew its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 26.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,038,990 shares of the biopharmaceutical company's stock after purchasing an additional 216,882 shares during the period. Deutsche Bank AG owned approximately 0.34% of Amicus Therapeutics worth $8,478,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Virtus Fund Advisers LLC bought a new position in Amicus Therapeutics in the 4th quarter worth about $29,000. PNC Financial Services Group Inc. grew its position in Amicus Therapeutics by 211.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 3,497 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Amicus Therapeutics in the 4th quarter worth about $59,000. GAMMA Investing LLC grew its position in Amicus Therapeutics by 1,610.8% in the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock worth $61,000 after purchasing an additional 7,007 shares during the last quarter. Finally, Bryce Point Capital LLC bought a new position in Amicus Therapeutics in the 1st quarter worth about $100,000.

Analysts Set New Price Targets

Several research firms have recently issued reports on FOLD. UBS Group increased their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday, May 2nd. The Goldman Sachs Group decreased their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Wall Street Zen raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday, July 17th. Eight research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Stock Down 0.9%

Shares of Amicus Therapeutics stock traded down $0.0650 during midday trading on Tuesday, reaching $7.3450. 935,467 shares of the company's stock traded hands, compared to its average volume of 3,881,554. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -61.20 and a beta of 0.53. The company's 50 day simple moving average is $6.24 and its 200 day simple moving average is $7.22. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $12.65.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.